HC Wainwright Has Positive Estimate for Precigen Q3 Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Precigen to $0.00 (from -$0.01), maintaining a Buy rating and a $10 price target while projecting EPS growth to $1.02 by FY2030.
• Precigen beat Q4 EPS (-$0.01 vs. -$0.10 consensus) but missed revenue expectations ($4.57M vs. ~$8.29M); nonetheless, commercial momentum for PAPZIMEOS (reported $3.4M net product revenue in Q4), a permanent CMS J‑code, and guidance for Q1 revenue >$18M support management's path toward 2026 cash‑flow breakeven.
• Shares jumped ~25% after the results, yet analyst views remain mixed (consensus "Hold" with a $9.50 average target) even as institutional buying has increased, highlighting both renewed optimism and near‑term valuation risk.

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Investment analysts at HC Wainwright lifted their Q3 2026 earnings estimates for Precigen in a research report issued to clients and investors on Thursday, March 26th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings per share of $0.00 for the quarter, up from their prior estimate of ($0.01). HC Wainwright currently has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen's FY2027 earnings at $0.22 EPS, FY2028 earnings at $0.44 EPS, FY2029 earnings at $0.69 EPS and FY2030 earnings at $1.02 EPS.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.09. Precigen had a negative net margin of 2,588.21% and a negative return on equity of 2,313.82%. The business had revenue of $4.57 million during the quarter, compared to analysts' expectations of $8.29 million.

A number of other equities analysts have also recently commented on PGEN. Zacks Research raised Precigen from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 10th. Citizens Jmp boosted their price target on Precigen from $8.00 to $9.00 and gave the company a "market outperform" rating in a report on Thursday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Precigen in a research report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $9.50.

Precigen Trading Up 25.3%

Shares of Precigen stock opened at $3.89 on Friday. Precigen has a 1-year low of $1.11 and a 1-year high of $5.47. The company's fifty day simple moving average is $4.10 and its 200-day simple moving average is $3.98. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.04 and a quick ratio of 3.95. The stock has a market capitalization of $1.37 billion, a PE ratio of -2.90 and a beta of 1.10.

Institutional Investors Weigh In On Precigen

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Patient Capital Management LLC lifted its position in shares of Precigen by 62.6% in the third quarter. Patient Capital Management LLC now owns 26,460,848 shares of the biotechnology company's stock valued at $87,056,000 after acquiring an additional 10,192,107 shares in the last quarter. State Street Corp raised its stake in Precigen by 141.1% during the fourth quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company's stock valued at $45,248,000 after purchasing an additional 6,335,033 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Precigen by 15.9% during the 4th quarter. Geode Capital Management LLC now owns 4,462,078 shares of the biotechnology company's stock valued at $18,653,000 after buying an additional 613,340 shares in the last quarter. Occam Crest Management LP raised its position in shares of Precigen by 29.6% during the 4th quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company's stock valued at $14,637,000 after buying an additional 799,339 shares in the last quarter. Finally, SymBiosis Capital Partners LLC purchased a new position in Precigen in the fourth quarter worth about $12,540,000. 33.51% of the stock is owned by institutional investors.

Precigen News Summary

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: PAPZIMEOS commercial momentum: Precigen reported PAPZIMEOS generated $3.4M in net product revenue in Q4 (partial quarter) and said demand picked up sharply into Q1; company has $100.4M in cash to fund operations toward a 2026 cash-flow breakeven target. Precigen Reports Full Year 2025 Financial Results and Business Updates
• Positive Sentiment: Company guidance and payer progress: Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates with broad U.S. payer coverage; CMS assigned a permanent J‑code (J3404) effective Apr 1, which should streamline reimbursement. Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates with broad U.S. payer coverage
• Positive Sentiment: Analyst upgrades and higher targets: Multiple firms raised price targets and ratings after the results (HC Wainwright to $10 buy; Citizens JMP to $9 market outperform), reflecting expectations for meaningful upside as the commercial rollout scales. These Analysts Boost Their Forecasts On Precigen Following Q4 Results
• Positive Sentiment: Bull thesis and modeled upside: A recent deep-dive bullish note highlights PAPZIMEOS’s blockbuster potential, models Q1 run-rate and payer traction, and produces a probability-weighted fair value (~$6.13–$7.01 per share) above current levels. Precigen: The Best Potential Blockbuster You've Never Heard Of (Your ENT Has)
• Neutral Sentiment: Earnings call and transcripts available: Management held its full-year 2025 call and provided operational color on commercial expansion and an open‑label redosing study; transcripts and call highlights are published. Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 revenue missed estimates: Reported EPS beat slightly (smaller loss) but Q4 revenue was $4.57M vs. consensus ~$8.29M; the company still shows deep negative margins and high leverage metrics, which are risks until commercial revenues scale. Precigen (PGEN) Q4 2025 Earnings / MarketBeat
• Negative Sentiment: Valuation and momentum caution: Coverage pieces note PGEN’s ~145% one‑year run, and some investors may view current gains as late-stage momentum, raising near-term valuation risk if launch cadence or reimbursement lags expectations. Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?

Precigen Company Profile

Precigen, Inc NASDAQ: PGEN is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen's approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen's technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.